Therapeutic approaches for Duchenne muscular dystrophy

Area of Science:

• Biomedical Science
• Genetics
• Neurology

Background:

• Duchenne muscular dystrophy (DMD) is a rare, inherited muscle-wasting disease affecting children.
• It stems from mutations disrupting dystrophin protein production, crucial for muscle integrity.
• DMD is the most common inherited myopathy in children, driving significant research.

Purpose of the Study:

• To review current and emerging therapeutic strategies for Duchenne muscular dystrophy.
• To highlight the impact of DMD drug development on broader molecular and cellular medicine.
• To position DMD as a pioneering disease for future genetic therapy research.

Main Methods:

• Review of current therapeutic approaches for DMD.
• Discussion of drug development programs targeting dystrophin restoration.
• Analysis of clinical approvals and ongoing research in DMD therapeutics.

Main Results:

• Several therapeutic strategies are in development for DMD, including exon skipping, stop codon readthrough, gene replacement, cell therapy, and gene editing.
• Four exon skipping antisense oligonucleotides, one stop codon readthrough drug, and one gene therapy product have received clinical approval.
• Further approvals for DMD treatments are anticipated soon.

Conclusions:

• DMD is a leading area for molecular and cellular therapeutics, with ongoing research yielding approved treatments.
• The advancements in DMD therapies are paving the way for similar approaches in other genetic diseases.
• DMD serves as a model for future drug discovery in genetic medicine.